News of Note—Stent trial controversy, Corindus funding and more

Newspapers
(NS Newsflash/CC BY 2.0)

> Controversy has engulfed a long-running study into the use of stents in patients with stable ischemic heart disease. The row blew up after investigators changed the primary endpoint late in the study. CardioBrief

> Corindus, a provider of robotic-assisted vascular intervention technologies, has put together a $25 million private placement. Statement

> Nexstim has ended negotiations with a potential Chinese distribution partner. The neuromodulation company had hoped to receive a $1.2 million investment through the deal. Release

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

Five years after Congress passed a law to reduce unnecessary MRIs and CT scans, federal officials have yet to implement it.